Development of a charter for an endpoint assessment and adjudication committee

Drug Information Journal

Volumn 39, Issue 1, 2005, Pages 53-61

  Kradjian, Steve ^a,c   Gutheil, John ^a,d   Baratelle, Anna M ^b   Einstein, Steven G ^b   Kaslow, David C ^a  

^a VICAL INC   (United States)

^b BioClinica Inc   (United States)

^c Kradjian Consulting   (United States)

^d Favrille Inc   (United States)

Author keywords

Committee charter; Data Monitoring Committee; Endpoint; Endpoint assessment; Endpoint Assessment and Adjudication; Pivotal trial

Indexed keywords

ALLOVECTIN 7; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; DACARBAZINE; HLA B7 ANTIGEN; IMMUNOMODULATING AGENT; PLASMID DNA; UNCLASSIFIED DRUG;

CANCER; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; ENDPOINT ASSESSMENT AND ADJUDICATION COMMITTEE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; LABORATORY DIAGNOSIS; MULTICENTER STUDY; OPEN STUDY; ORGANIZATION; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT;

EID: 13844275035     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150503900107     Document Type: Review

References (8)

1. Bristol Made Deal With ImClone Without Key Data, Panel Says. New York Times. June 15, 2002.
2. Good Clinical Practice: Consolidated Guideline (www.ich.org/pdfICH/e6. pdf). Federal Register. 62: 25691.
3. Title 21 §312.56 Code of Federal Regulations. Washington, DC: April 1, 2003.
4. Draft Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. http://www.fda.gov/cber/ gdlns/clindatmon.pdf. Federal Register. 66:58151.
5. Title 21 Code of Federal Regulations. 50, 56, 312. Washington, DC: April 1, 2003.
6. Except where the informed consent requirement has been waived in emergency settings; Title 21 Code of Federal Regulations 50.24 (a)(7)(iv). Washington, DC: April 1, 2003.
7. Open Public Meeting: FDA Guidance on Clinical Trial Data Monitoring Committees (DMCS), November 27, 2001, Bethesda, MD. http://www.fda.gov/cber/ minutes/workshop-min.htm.
8. Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med. 2002;21(19):2843-2851.